Donanemab, Florbetapir F18, Flortaucipir F18, Flortaucipir, FLORBETAPIR, SODIUM CHLORIDE PH. EUR.
I5T-MC-AACO
Phase 3 small_molecule active
Quick answer
Donanemab, Florbetapir F18, Flortaucipir F18, Flortaucipir, FLORBETAPIR, SODIUM CHLORIDE PH. EUR. for Alzheimer Disease Dementia Brain Diseases Central Nervous System Diseases Nervous System Diseases Tauopathies Neurodegenerative Diseases Neurocognitive Disorders Mental Disorders is a Phase 3 program (small_molecule) at Eli Lilly Co. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Eli Lilly Co.
- Indication
- Alzheimer Disease Dementia Brain Diseases Central Nervous System Diseases Nervous System Diseases Tauopathies Neurodegenerative Diseases Neurocognitive Disorders Mental Disorders
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active